Sustained release of brimonidine from BRI@SR@TPU implant for treatment of glaucoma

Glaucoma is the leading cause of irreversible vision loss worldwide, and reduction of intraocular pressure (IOP) is the only factor that can be interfered to delay disease progression. As the first line and preferred method to treat glaucoma, eye drops have many shortcomings, such as low bioavailabi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Yujin, Huang, Chang, Zhang, Zhutian, Hong, Jiaxu, Xu, Jianjiang, Sun, Xinghuai, Sun, Jianguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8856066/
https://www.ncbi.nlm.nih.gov/pubmed/35174743
http://dx.doi.org/10.1080/10717544.2022.2039806

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8856066/
https://www.ncbi.nlm.nih.gov/pubmed/35174743
http://dx.doi.org/10.1080/10717544.2022.2039806

Ejemplares similares